Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) traded up 3.2% during mid-day trading on Tuesday . The stock traded as high as $5.16 and last traded at $5.09, with a volume of 163,837 shares. The stock had previously closed at $4.93.

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating on shares of Tobira Therapeutics in a report on Wednesday, May 4th. Leerink Swann restated a “buy” rating on shares of Tobira Therapeutics in a report on Monday, May 2nd. Zacks Investment Research downgraded Tobira Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Cantor Fitzgerald downgraded Tobira Therapeutics to a “buy” rating and set a $19.00 target price on the stock. in a report on Monday, July 25th. Finally, Cowen and Company reiterated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Five investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $16.75.

The firm’s 50-day moving average price is $6.42 and its 200 day moving average price is $8.25. The firm’s market cap is $93.73 million.

Tobira Therapeutics (NASDAQ:TBRA) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. The firm earned $1.06 million during the quarter. Analysts forecast that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current fiscal year.

In related news, major shareholder A/S Novo sold 59,067 shares of the firm’s stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total value of $709,985.34. Following the transaction, the insider now owns 1,914,541 shares in the company, valued at $23,012,782.82. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP bought a new position in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics as of its most recent filing with the SEC.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.